scholarly journals Network Pharmacology Approach for Predicting Targets of Zishen Yutai Pills on Premature Ovarian Insufficiency

2021 ◽  
Vol 2021 ◽  
pp. 1-15
Author(s):  
Yihui Feng ◽  
Xinyi Chai ◽  
Yingyin Chen ◽  
Yan Ning ◽  
Ying Zhao
Keyword(s):  
Molecular Docking ◽  
Chinese Medicine ◽  
Glucose Metabolism ◽  
Target Genes ◽  
Premature Ovarian Insufficiency ◽  
Network Pharmacology ◽  
Biological Processes ◽  
Ovarian Insufficiency ◽  
Active Compounds ◽  
Pharmacological Mechanism

Background and Purpose. Premature ovarian insufficiency (POI) is a serious reproductive disease in females that is characterized by menstrual and ovulation disorders and infertility. The clinical efficacy of complementary and alternative medicine (CAM) has been reported in POI, including compound Chinese medicine. Zishen Yutai Pills (ZSYTP), a well-known patented Chinese medicine, has been widely used for treating POI; however, the pharmacological mechanism and molecular targets of ZSYTP remain unknown. Here, we systematically elucidated the pharmacological mechanism of ZSYTP on POI using a network pharmacology approach and further validated our findings with molecular docking. Methods. A comprehensive strategy based on several Chinese herb databases and chemical compound databases was established to screen active compounds of ZSYTP and predict target genes. For network pharmacological analysis, network construction and gene enrichment analysis were conducted and further verified by molecular docking. Results. A total of 476 target genes of ZSYTP were obtained from 205 active compounds. 13 herbs of ZSYTP overlapped on 8 active compounds based on the compound-target-disease network (C-T network). 20 biological processes and 9 pathways were strongly connected to the targets of ZSYTP in treating POI, including negative regulation of gene expression, mRNA metabolic process, hypoxia-inducible factor 1 (HIF-1) signaling pathway, and gluconeogenesis. Finally, molecular docking was visualized. Conclusion. Intriguingly, the signal pathways and biological processes uncovered in this study implicate inflamm-aging and glucose metabolism as potential pathological mechanisms of POI. The therapeutic effect of ZSYTP could be mediated by regulating glucose metabolism and HIF-1 signal pathway. Collectively, this study sheds light on the therapeutic potential of ZSYTP on POI.

scholarly journals Research on Active Compounds of Huanglian Jiedu Decoction for the Treatment of Corona Virus Disease 2019 Based on Network Pharmacology and Molecular Docking

2020 ◽  
Author(s):  
Leping Liu ◽  
Xinyi Xu ◽  
Xueshuai Cao ◽  
Xi Long ◽  
Yanwei Luo ◽  
...  
Keyword(s):  
Molecular Docking ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Signaling Pathways ◽  
Target Genes ◽  
Virus Disease ◽  
Network Pharmacology ◽  
Signal Pathways ◽  
Active Compounds ◽  
Corona Virus

Abstract Background Huanglian Jiedu Decoction (HLJDD) is a traditional Chinese prescription for the treatment of influenza, inflammation and other ailments related to heat-syndrome, a typical pathological symptom in Traditional Chinese Medicine. It was recommended as one of the basic prescriptions among the Proposed Diagnoses and Treatment issued by China’s National Health Commission. In this work we investigated the molecular mechanism of action of Huanglian Jiedu Decoction in the treatment of Corona Virus Disease 2019 (COVID-19) through network pharmacology and molecular docking approaches. Methods The chemical constituents and action targets of Coptis chinensis, Scutellaria baicalensis, Phellodendron amurense, Gardenia jasminoides in HLJDD were retrieved on Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). The database of UniProt and GeneCards were used to query the target genes that corresponding to the active compounds, and then a compound-target network was constructed using Cytoscape 3.7.2. GO database was used to annotate GO functions. Reactome was used to analyze KEGG enrichment pathway, predicting the possible mechanisms of active compounds. DAVID database was used to analysis the tissue enrichment. The main active ingredient is molecularly docked with the SARS-CoV-2, ACE2 and TMPRSS2. Results We screened 84 compounds and obtained 341 corresponding target genes in the network. Gene annotation showed that the targets were involved mainly in 457 biological functions. 306 signaling pathways was enriched, involving chemokine and cytokine signaling pathways that mediate inflammation, interferon-γ signaling pathway, p53 pathway. And the targets mainly distributed in the lung liver and placenta, involving a variety of immune cells, such as T cells, B cells. The molecular docking results showed that core compounds such as beta-sitosterol, stigmasterol and quercetin had high affinity with SARS-CoV-2, ACE2 and TMPRSS2, which was comparable with drugs like abidol used to COVID-19 treatment by. Conclusions The active compounds in HLJDD may have a therapeutic effect on COVID-19 through regulating multiple signal pathways by targeting genes such as VEGF, NOS2, IL6, MMP9, IL10, and TGFB1.

scholarly journals Identifying Active Compounds and Targets of Fritillariae thunbergii against Influenza-Associated Inflammation by Network Pharmacology Analysis and Molecular Docking

Molecules ◽  
2020 ◽  
Vol 25 (17) ◽  
pp. 3853 ◽  
Author(s):  
Minjee Kim ◽  
Ki Hoon Park ◽  
Young Bong Kim
Keyword(s):  
Molecular Docking ◽  
Binding Affinity ◽  
Target Genes ◽  
Inflammatory Diseases ◽  
Network Pharmacology ◽  
Pharmacokinetic Parameters ◽  
Active Compounds ◽  
Biological Targets ◽  
Underlying Mechanisms ◽  
Cox 1

Complications due to influenza are often associated with inflammation with excessive release of cytokines. The bulbs of Fritillariae thunbergii (FT) have been traditionally used to control airway inflammatory diseases, such as bronchitis and pneumonia. To elucidate active compounds, the targets, and underlying mechanisms of FT for the treatment of influenza-induced inflammation, systems biology was employed. Active compounds of FT were identified through the TCMSP database according to oral bioavailability (OB) and drug-likeness (DL) criteria. Other pharmacokinetic parameters, Caco-2 permeability (Caco-2), and drug half-life (HL) were also identified. Biological targets of FT were retrieved from DrugBank and STITCH databases, and target genes associated with influenza, lung, and spleen inflammation were collected from DisGeNET and NCBI databases. Compound-disease-target (C-D-T) networks were constructed and merged using Cytoscape. Target genes retrieved from the C-D-T network were further analyzed with GO enrichment and KEGG pathway analysis. In our network, GO and KEGG results yielded two compounds (beta-sitosterol (BS) and pelargonidin (PG)), targets (PTGS1 (COX-1) and PTGS2 (COX-2)), and pathways (nitric oxide, TNF) were involved in the inhibitory effects of FT on influenza-associated inflammation. We retrieved the binding affinity of each ligand-target, and found that PG and COX-1 showed the strongest binding affinity among four binding results using a molecular docking method. We identified the potential compounds and targets of FT against influenza and suggest that FT is an immunomodulatory therapy for influenza-associated inflammation.

scholarly journals Revealing the Pharmacological Mechanism of Acorus tatarinowii in the Treatment of Ischemic Stroke Based on Network Pharmacology

2020 ◽  
Vol 2020 ◽  
pp. 1-16
Author(s):  
FengZhi Liu ◽  
Qian Zhao ◽  
Suxian Liu ◽  
Yingzhi Xu ◽  
Dongrui Zhou ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Target Genes ◽  
Enrichment Analysis ◽  
Basic Mechanism ◽  
Signal Pathway ◽  
Network Pharmacology ◽  
Active Compounds ◽  
Pharmacological Mechanism ◽  
Interactive Network ◽  
Acorus Tatarinowii

Aim. Stroke is the second significant cause for death, with ischemic stroke (IS) being the main type threatening human being’s health. Acorus tatarinowii (AT) is widely used in the treatment of Alzheimer disease, epilepsy, depression, and stroke, which leads to disorders of consciousness disease. However, the systemic mechanism of AT treating IS is unexplicit. This article is supposed to explain why AT has an effect on the treatment of IS in a comprehensive and systematic way by network pharmacology. Methods and Materials. ADME (absorbed, distributed, metabolized, and excreted) is an important property for screening-related compounds in AT, which were screening out of TCMSP, TCMID, Chemistry Database, and literature from CNKI. Then, these targets related to screened compounds were predicted via Swiss Targets, when AT-related targets database was established. The gene targets related to IS were collected from DisGeNET and GeneCards. IS-AT is a common protein interactive network established by STRING Database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment were analysed by IS-AT common target genes. Cytoscape software was used to establish a visualized network for active compounds-core targets and core target proteins-proteins interactive network. Furthermore, we drew a signal pathway picture about its effect to reveal the basic mechanism of AT against IS systematically. Results. There were 53 active compounds screened from AT, inferring the main therapeutic substances as follows: bisasaricin, 3-cyclohexene-1-methanol-α,α,4-trimethyl,acetate, cis,cis,cis-7,10,13-hexadecatrienal, hydroxyacoronene, nerolidol, galgravin, veraguensin, 2′-o-methyl isoliquiritigenin, gamma-asarone, and alpha-asarone. We obtained 398 related targets, 63 of which were the same as the IS-related genes from targets prediction. Except for GRM2, remaining 62 target genes have an interactive relation, respectively. The top 10 degree core target genes were IL6, TNF, IL1B, TLR4, NOS3, MAPK1, PTGS2, VEGFA, JUN, and MMP9. There were more than 20 terms of biological process, 7 terms of cellular components, and 14 terms of molecular function through GO enrichment analysis and 13 terms of signal pathway from KEGG enrichment analysis based on P < 0.05 . Conclusion. AT had a therapeutic effect for ischemic via multicomponent, multitarget, and multisignal pathway, which provided a novel research aspect for AT against IS.

scholarly journals A Network Pharmacology-Based Study on the Anti-Lung Cancer Effect of Dipsaci Radix

2020 ◽  
Vol 2020 ◽  
pp. 1-9 ◽  
Author(s):  
Jiayan Wu ◽  
Shengkun Hong ◽  
Xiankuan Xie ◽  
Wangmi Liu
Keyword(s):  
Lung Cancer ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Molecular Mechanisms ◽  
Target Genes ◽  
Interaction Network ◽  
Network Pharmacology ◽  
Pathway Enrichment Analysis ◽  
Hub Genes ◽  
Active Compounds

Objective. Dipsaci Radix (DR) has been used to treat fracture and osteoporosis. Recent reports have shown that myeloid cells from bone marrow can promote the proliferation of lung cancer. However, the action and mechanism of DR has not been well defined in lung cancer. The aim of the present study was to define molecular mechanisms of DR as a potential therapeutic approach to treat lung cancer. Methods. Active compounds of DR with oral bioavailability ≥30% and drug-likeness index ≥0.18 were obtained from the traditional Chinese medicine systems pharmacology database and analysis platform. The potential target genes of the active compounds and bone were identified by PharmMapper and GeneCards, respectively. The compound-target network and protein-protein interaction network were built by Cytoscape software and Search Tool for the Retrieval of Interacting Genes webserver, respectively. GO analysis and pathway enrichment analysis were performed using R software. Results. Our study demonstrated that DR had 6 active compounds, including gentisin, sitosterol, Sylvestroside III, 3,5-Di-O-caffeoylquinic acid, cauloside A, and japonine. There were 254 target genes related to these active compounds as well as to bone. SRC, AKT1, and GRB2 were the top 3 hub genes. Metabolisms and signaling pathways associated with these hub genes were significantly enriched. Conclusions. This study indicated that DR could exhibit the anti-lung cancer effect by affecting multiple targets and multiple pathways. It reflects the traditional Chinese medicine characterized by multicomponents and multitargets. DR could be considered as a candidate for clinical anticancer therapy by regulating bone physiological functions.

scholarly journals Network Pharmacology Identifies the Mechanisms of Action of Tongxie Anchang Decoction in the Treatment of Irritable Bowel Syndrome with Diarrhea Predominant

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Xiang Tan ◽  
Wenjing Pei ◽  
Chune Xie ◽  
Zhibin Wang ◽  
Tangyou Mao ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Target Genes ◽  
Alternative Therapy ◽  
Enrichment Analysis ◽  
Network Pharmacology ◽  
Active Compounds ◽  
Complementary And Alternative Therapy ◽  
Pharmacological Mechanism ◽  
Target Network ◽  
Irritable Bowel

Aim. This study aims to uncover the pharmacological mechanism of Tongxie Anchang Decoction (TXACD), a new and effective traditional Chinese medicine (TCM) prescription, for treating irritable bowel syndrome with diarrhea predominant (IBS-D) using network pharmacology. Methods. The active compounds and putative targets of TXACD were retrieved from TCMSP database and published literature; related target genes of IBS-D were retrieved from GeneCards; PPI network of the common target hub gene was constructed by STRING. Furthermore, these hub genes were analyzed using gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Results. A total of 54 active compounds and 639 targets were identified through a database search. The compound-target network was constructed, and the key compounds were screened out according to the degree. By using the PPI and GO and KEGG enrichment analyses, the pharmacological mechanism network of TXACD in the treatment of IBS-D was constructed. Conclusions. This study revealed the possible mechanisms by which TXACD treatment alleviated IBS-D involvement in the modulation of multiple targets and multiple pathways, including the immune regulation, inflammatory response, and oxidative stress. These findings provide novel insights into the regulatory role of TXACD in the prevention and treatment of IBS-D and hold promise for herb-based complementary and alternative therapy.

scholarly journals Exploring the Mechanisms of Lian Hua Qing Wen Capsule against COVID-19 by Network Pharmacology and Molecular Docking Approach

2020 ◽  
Author(s):  
Li Chen ◽  
Hua Qu ◽  
Yu Tan ◽  
Tao Han Wu ◽  
Zhuo Da Shi
Keyword(s):  
Molecular Docking ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Signaling Pathway ◽  
Target Genes ◽  
Enrichment Analysis ◽  
Active Compounds ◽  
Related Target ◽  
Docking Approach ◽  
Omim Database

Abstract Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) disease has led to a wide-spread global pandemic. There is no specific antiviral drug proven effective for the treatment of patients with COVID-19 at present. Combination of western and traditional Chinese medicine (TCM) is recommended, and Lian Hua Qing Wen (LHQW) capsule is a basic prescription and widely used to treat COVID-19 in China. However, the mechanisms of LHQW capsule treating COVID-19 are not clear. The aim of the study is to explore the mechanisms of LHQW capsule treating COVID-19 based on network pharmacy and molecular docking approach. Methods The active compounds and targets of LHQW capsule were obtained from traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP). COVID-19 related target genes were obtained from GeneCards database and OMIM database. Protein–protein interaction (PPI) networks of LHQW capsule targets and COVID-19-related genes were visualized and merged to identify the candidate targets for LHQW capsule treating COVID-19. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were also performed. The hub genes involved in the gene-related pathways were screened and their corresponding compounds were used for in vitro validation of molecular docking predictions.Results A total of 185 active compounds of LHQW capsule were screened out, and 263 targets were predicted. Third hundred and fifty-two COVID-19 related target genes were obtained from GeneCards database and OMIM database. GO functional enrichment analysis showed that the biological processes of LHQW capsule treating COVID-19 were closely linked with the regulation of inflammation, immunity, cytokines production, vascular permeability, oxidative stress and apoptosis. KEGG enrichment analysis revealed that the pathways of LHQW capsule treating COVID-19 were significantly enriched in AGE−RAGE signaling pathway in diabetic complications, Kaposi sarcoma−associated herpesvirus infection, TNF, IL−17, and Toll−like receptor (TLR) signaling pathway. The hub targets genes in the gene-related pathways analysis of LHQW capsule treating COVID-19 included MAPK1, MAPK3, RELA, IL-6 and CASP8, which closely associated with inflammation, cytokines storm and apoptosis. Finally, molecular docking showed that top 5 compounds of LHQW capsule also had good binding activities to the important targets in COVID-19.Conclusions The mechanisms of LHQW capsule treating COVID-19 may involve in inhibiting inflammatory response, cytokine storm and virus infection, and regulating immune reactions, apoptosis and endothelial barrier.

scholarly journals Deciphering the Key Pharmacological Pathways and Targets of Yisui Qinghuang Powder That Acts on Myelodysplastic Syndromes Using a Network Pharmacology-Based Strategy

2020 ◽  
Vol 2020 ◽  
pp. 1-12
Author(s):  
Zijian Han ◽  
Luping Song ◽  
Kele Qi ◽  
Yang Ding ◽  
Mingjun Wei ◽  
...  
Keyword(s):  
Myelodysplastic Syndromes ◽  
Target Genes ◽  
Network Pharmacology ◽  
Analysis Tool ◽  
Antitumor Effects ◽  
Active Compounds ◽  
Pharmacological Mechanism ◽  
Putative Target ◽  
Target Disease ◽  
Qinghuang Powder

Background. Yisui Qinghuang powder (YSQHP) is an effective traditional Chinese medicinal formulation used for the treatment of myelodysplastic syndromes (MDS). However, its pharmacological mechanism of action is unclear. Materials and Methods. In this study, the active compounds of YSQHP were screened using the traditional Chinese medicine systems pharmacology (TCMSP) and HerDing databases, and the putative target genes of YSQHP were predicted using the STITCH and DrugBank databases. Then, we further screened the correlative biotargets of YSQHP and MDS. Finally, the compound-target-disease (C-T-D) network was conducted using Cytoscape, while GO and KEGG analyses were conducted using R software. Furthermore, DDI-CPI, a web molecular docking analysis tool, was used to verify potential targets and pathways. Finally, binding site analysis was performed to identify core targets using MOE software. Results. Our results identified 19 active compounds and 273 putative target genes of YSQHP. The findings of the C-T-D network revealed that Rb1, CASP3, BCL2, and MAPK3 showed the most number of interactions, whereas indirubin, tryptanthrin, G-Rg1, G-Rb1, and G-Rh2 showed the most number of potential targets. The GO analysis showed that 17 proteins were related with STPK activity, PUP ligase binding, and kinase regulator activity. The KEGG analysis showed that PI3K/AKT, apoptosis, and the p53 pathways were the main pathways involved. DDI-CPI identified the top 25 proteins related with PI3K/AKT, apoptosis, and the p53 pathways. CASP8, GSK3B, PRKCA, and VEGFR2 were identified as the correlative biotargets of DDI-CPI and PPI, and their binding sites were found to be indirubin, G-Rh2, and G-Rf. Conclusion. Taken together, our results revealed that YSQHP likely exerts its antitumor effects by binding to CASP8, GSK3B, PRKCA, and VEGFR2 and by regulating the apoptosis, p53, and PI3K/AKT pathways.

scholarly journals Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6

2020 ◽  
Author(s):  
Chun Liang ◽  
Wenhao Niu ◽  
Feng Wu ◽  
Wenyue Cao ◽  
Zonggui Wu ◽  
...  
Keyword(s):  
Molecular Docking ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Binding Affinity ◽  
Ursolic Acid ◽  
Interleukin 6 ◽  
Chemical Constituents ◽  
Gene Clusters ◽  
Network Pharmacology ◽  
Biological Processes

Objective: “Three formulas and three medicines,” namely, Jinhua Qinggan Granule, Lianhua Qingwen Capsule, Xuebijing Injection, Qingfei Paidu Decoction, HuaShi BaiDu Formula, and XuanFei BaiDu Granule, were proven to be effective for coronavirus disease 2019 (COVID-19) treatment. This study aimed to identify the active chemical constituents of this traditional Chinese medicine (TCM) and investigate their mechanisms through interleukin-6 (IL-6) integrating network pharmacological approaches.Methods: We collected the compounds from all herbal ingredients of the previously mentioned TCM, but those that could downregulate IL-6 were screened through the network pharmacology approach. Then, we modeled molecular docking to evaluate the binding affinity between compounds and IL-6. Furthermore, we analyzed the biological processes and pathways of compounds. Lastly, we screened out the core genes of compounds through the construction of the protein-protein interaction network and the excavation of gene clusters of compounds.Results: The network pharmacology research showed that TCM could decrease IL-6 using several compounds, such as quercetin, ursolic acid, luteolin, and rutin. Molecular docking results showed that the molecular binding affinity with IL-6 of all compounds except γ-aminobutyric acid was &lt; −5.0 kJ/mol, indicating the potential of numerous active compounds in TCM to directly interact with IL-6, leading to an anti-inflammation effect. Finally, Cytoscape 3.7.2 was used to topologize the biological processes and pathways of compounds, revealing potential mechanisms for COVID-19 treatment.Conclusion: These results indicated the positive effect of TCM on the prevention and rehabilitation of COVID-19 in at-risk people. Quercetin, ursolic acid, luteolin, and rutin could inhibit COVID-19 by downregulating IL-6.

Exploring the mechanisms of Drynariae Rhizoma on treating memory impairment through network pharmacology

2021 ◽  
Author(s):  
Wangmi Liu ◽  
Jiayan Wu
Keyword(s):  
Molecular Docking ◽  
Nerve Growth Factor ◽  
Chinese Medicine ◽  
Growth Factor ◽  
Traditional Chinese Medicine ◽  
Memory Impairment ◽  
Network Pharmacology ◽  
Active Compounds ◽  
Major Health Problem ◽  
Nerve Growth

Abstract Background Memory impairment continues to be a major health problem and increases with age, especially in the elderly population worldwide. However, a causal mechanism has not been clearly identified. Currently, an interaction between bone and brain, the so-called “bone-brain crosstalk,” has emerged. We used a network pharmacology approach to explore the potential mechanisms of Drynariae Rhizoma (DR), a traditional Chinese medicine for fracture treatment, for therapeutic intervention of human conditions associated with memory impairment. Methods The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform was used to screen out the active compounds of DR, and the targets of the active compounds were predicted using PharmMapper. Targets related to memory impairment were downloaded from the DisGeNET database. The compound-target network and protein-protein interaction network were built by NetworkAnalyst and Cytoscape software. Gene ontology analysis and Reactome pathway enrichment analysis were performed using NetworkAnalyst. SYBYL-X software was used to perform molecular docking simulation. Results Our study demonstrated that DR had 7 active compounds. There were 60 target genes related to these active compounds as well as to memory impairment. Signalling by nerve growth factor was among the top 3 enriched Reactome terms. Akt1 was an important signalling hub gene belonging to signalling by nerve growth factor pathway. Molecular docking results showed that the one of the active compounds, xanthogalenol, exhibited acceptable affinities to Akt1. Conclusion This study demonstrated the molecular mechanism that DR may alleviate memory impairment via regulation of Akt1 and signalling by nerve growth factor pathway. These results offer new ideas in searching for novel strategies for the treatment of memory impairment.

scholarly journals The molecular mechanism of TiaoGanYiPi formula for treatment of chronic hepatitis B by network pharmacology and molecular docking verification

2020 ◽  
Author(s):  
Xu Cao ◽  
Xiaobin Zao ◽  
Baiquan Xue ◽  
Hening Chen ◽  
Jiaxin Zhang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Molecular Docking ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Target Genes ◽  
Regulation Of Gene Expression ◽  
Interaction Network ◽  
Network Pharmacology ◽  
Biological Processes ◽  
The Relationship

Abstract The Chinese herbal formula Tiao-Gan-Yi-Pi (TGYP) showed effective against Chronic Hepatitis B (CHB). In this study, we aimed to clarify the mechanisms and potential targets between TGYP and CHB through network pharmacology and molecular docking verification. The compounds of TGYP were identified in the TCMSP and CNKI databases, and their putative targets were predicted through SwissTargetPrediction and STITCH databases. The targets of CHB were obtained from the GeneCards, NCBI Gene, and DisGeNET databases. The above mentioned data were visualized using Cytoscape, and molecular docking showed the relationship between them. The expression of key targets was verified in GEO databases. Hence, we screened out 11 TGYP-related key targets for CHB included ABL1, CASP8, CCNA2, CCNB1, CDK4, CDKN1A, EP300, HIF1A, IGF1R, MAP2K1 and PGR. The key targets were predominantly enriched in the cancer, cell cycle and hepatitis B pathways and involved in the positive regulation of fibroblast proliferation, signal transduction, and negative regulation of gene expression biological processes, and expression of key target genes was related to HBV infection and liver inflammation. Through this newly constructed interaction network between TGYP and CHB, we identified active compounds and targets which could be further used for providing clinical guidance.

Sign in / Sign up

Export Citation Format

Share Document